Regular and timely review, appraisal and communication of safety information are critical to risk management during the clinical development of drugs. Whereas the overall goal of a clinical development programme is to characterize the benefit-risk relationship of the product in a particular patient population, the risk to individual trial subjects is a critical consideration during product development, at a time when the effectiveness of a product is generally uncertain. By conducting an overall appraisal of safety data at regular intervals, risks can be recognised, thoughtfully assessed, and appropriately communicated to all interested stakeholders, to support the safety of clinical trial subjects.Although regulatory authorities currently require the submission of a periodic safety report during the conduct of clinical trials, there are substantial differences in the format, content and timing of the different reports. The CIOMS VII Working group is proposing, in this new publication, an internationally harmonized document, namely, the Development Safety Update Report (DSUR), which is modeled after the Periodic Safety Update Report (PSUR) for marketed products. It presents the general principles behind the preparation and use of the DSUR, and a model DSUR. The model is illustrated with sample, fictitious DSURs for a commercial and non-commercial (trial-specific) sponsor.
Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.
Regular and timely review, appraisal and communication of safety information are critical to risk management during the clinical development of drugs. Whereas the overall goal of a clinical development programme is to characterize the benefit-risk relationship of the product in a particular patient population, the risk to individual trial subjects is a critical consideration during product development, at a time when the effectiveness of a product is generally uncertain. By conducting an overall appraisal of safety data at regular intervals, risks can be recognised, thoughtfully assessed, and appropriately communicated to all interested stakeholders, to support the safety of clinical trial subjects.Although regulatory authorities currently require the submission of a periodic safety report during the conduct of clinical trials, there are substantial differences in the format, content and timing of the different reports. The CIOMS VII Working group is proposing, in this new publication, an internationally harmonized document, namely, the Development Safety Update Report (DSUR), which is modeled after the Periodic Safety Update Report (PSUR) for marketed products. It presents the general principles behind the preparation and use of the DSUR, and a model DSUR. The model is illustrated with sample, fictitious DSURs for a commercial and non-commercial (trial-specific) sponsor.
„Über diesen Titel“ kann sich auf eine andere Ausgabe dieses Titels beziehen.
EUR 3,20 für den Versand innerhalb von/der USA
Versandziele, Kosten & DauerAnbieter: HPB-Red, Dallas, TX, USA
paperback. Zustand: Good. Connecting readers with great books since 1972! Used textbooks may not include companion materials such as access codes, etc. May have some wear or writing/highlighting. We ship orders daily and Customer Service is our top priority! Bestandsnummer des Verkäufers S_412647432
Anzahl: 1 verfügbar